HONG KONG – Chinese drugmakers have gotten a boost in the wake of the Chinese government's announcement to cut the value-added tax (VAT) on treatments for a range of rare diseases, in the country's latest move to overhaul its health care system and expand access to better-quality and cheaper drugs.